GSK Just Spent $1 Billion on a Cancer You've Probably Never Heard Of
GSK is paying up to $1.15 billion for a five-year-old biotech and its experimental drug targeting a rare cancer most people have never heard of. The bet: a single molecule that could crack the mutation problem that's haunted GIST treatment for two decades.
A Rare Tumor Gets a Big Check
Most people couldn't pick a gastrointestinal stromal tumor out of a lineup. GIST is a rare soft-tissue sarcoma that forms in the walls of the GI tract, and it affects a relatively small patient population. But GSK just wrote a check worth up to $1.15 billion to buy a tiny biotech called IDRx, and the reason comes down to one thing: a drug that might finally crack the mutation problem that's plagued GIST treatment for decades.
The deal closed as an all-cash transaction: $1 billion upfront with another $150 million tied to a regulatory milestone. For a company that was founded just five years ago and had raised roughly $242 million in venture funding, that's a tidy return. But the real question isn't whether IDRx's investors made money (they did). It's whether GSK is buying the right asset at the right time.
The Mutation Problem, Explained Simply
To understand why this deal matters, you need to understand how GIST works. About 80% of these tumors are driven by mutations in a gene called KIT. Think of KIT as a light switch stuck in the "on" position, telling cancer cells to keep growing. The first drug that figured out how to flip it off was imatinib, approved way back in 2002. It was revolutionary.
But cancer is a creative adversary. Over time, tumors develop new KIT mutations that let them dodge imatinib. Patients then cycle through second-line sunitinib, third-line regorafenib, and fourth-line ripretinib. Each one works for a while, then the tumor finds another workaround. It's like playing whack-a-mole with a mole that keeps growing new heads.
Advanced GIST is still considered incurable. The drugs buy time; they don't close the book. That's the unmet need GSK is betting on.
What IDRx Built
IDRx was born in 2021 out of Borisy Labs, the venture creation shop run by serial biotech entrepreneur Alexis Borisy. The founding team included George Demetri and , both heavyweights in the GIST and kinase inhibitor world. stepped in as CEO.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Nicholas Lydon
Ben Auspitz
The company's lead drug, IDRX-42 (now called velzatinib, or GSK6042981 if you prefer pharma's naming conventions), was licensed from Merck KGaA. It's a highly selective KIT inhibitor, but with one crucial difference from older drugs: it was designed to target all clinically relevant KIT mutations, not just the common ones. If imatinib is a key that fits one lock, velzatinib is supposed to be more like a master key.
The company also grabbed a second asset, IDRX-73, from Blueprint Medicines, though velzatinib is clearly the star of the show.
Funding came fast and heavy. A $122 million Series A in August 2022, led by Andreessen Horowitz and Casdin Capital, was reportedly oversubscribed. A $120 million Series B followed in August 2024 to push velzatinib deeper into the clinic.
The Clinical Picture
IDRx has been running a phased clinical program under the umbrella name StrateGIST:
StrateGIST 1: a Phase 1/1b first-in-human study testing velzatinib in patients with metastatic or surgically unresectable GIST who had already failed imatinib and other approved drugs. This was the safety and dose-finding stage.
StrateGIST 3: a Phase 3 randomized trial pitting velzatinib head-to-head against sunitinib in patients who progressed on imatinib.
There's also a frontline study comparing velzatinib directly to imatinib in previously untreated patients. That's ambitious; it signals IDRx (and now GSK) thinks this drug can compete not just as a backup option but as the starting pitcher.
Published summaries describe "encouraging activity" in heavily pretreated patients, with notable response rates in earlier-line settings. Those results were apparently convincing enough to justify the leap to Phase 3, and convincing enough for GSK to pay a billion dollars.
Why GSK, and Why Now?
GSK has been on an oncology shopping spree. The company spent years on the sidelines after divesting most of its cancer assets, and now it's trying to rebuild through targeted, bolt-on acquisitions rather than one massive transformational deal.
The strategy is clear: expand beyond blood and women's cancers into lung, GI, and prostate cancers, using a mix of antibody-drug conjugates (ADCs), next-gen small molecules, and T-cell engagers. As of mid-2026, GSK reported 7 assets across 18 indications and 20+ Phase III starts in its acceleration program. The IDRx deal slots velzatinib into the GI cancer bucket, filling a gap the company couldn't address internally.
GSK has also been pursuing Nuvalent for lung cancer and signed collaborations with Hengrui and LTZ Therapeutics, among others. The common thread: targeted bets in specific tumor types where biology is well understood and the competitive landscape isn't dominated by the mega-cap oncology players.
The Elephant in the Room
All this deal-making is happening while GSK simultaneously runs a £1.9 billion savings plan designed to fund pipeline growth, targeting annual savings by 2029. The company hasn't disclosed a specific headcount number for layoffs, but "self-funded savings" is corporate code for "we're cutting costs elsewhere to pay for this stuff." It's the biotech version of remodeling your kitchen while also tightening the household budget.
The tension is real. Employees watching colleagues get restructured out while the company writes billion-dollar acquisition checks have every right to raise an eyebrow. GSK's argument is that these investments are the growth engine; without them, there's nothing to restructure around. Whether that logic lands internally is another story.
Is It Worth a Billion?
One legal commentator noted that the offer reflected a premium for specialized rare-cancer assets, pointing out that IDRx had been valued much lower the prior year. The $150 million contingent payment was called a "sensible hedge," letting GSK manage downside risk if the drug stumbles at the regulatory finish line.
For a rare disease with limited competition and a drug that could theoretically serve patients across multiple lines of therapy (including frontline), $1.15 billion is aggressive but defensible. GIST isn't a blockbuster market by oncology standards, but if velzatinib delivers on its promise of covering all major KIT mutations, it could become the backbone of treatment. That kind of franchise value justifies a premium.
The bigger risk? Phase 3 data. Encouraging early results are just that: early. Plenty of drugs look great in Phase 1 and stumble when tested against an active comparator in a randomized setting. Sunitinib isn't a high bar, but it's a real one.
The Bottom Line
GSK is betting that a rare cancer with clear biology and a well-defined mutation target is worth a billion-dollar gamble. IDRx built the drug, assembled the team, and generated enough data to convince one of the world's largest pharma companies to buy the whole thing. Now it's GSK's job to get velzatinib across the finish line.
For GIST patients cycling through one failing drug after another, the stakes are a lot higher than any deal price. They just need the mole to stop growing new heads.
4 min read
Novartis Just Bet $7.8 Billion That Your Body Can Build Its Own Medicine
Novartis just paid $575 million upfront for access to Abogen's RNA technology, in a deal worth up to $7.8 billion. The bet: that your own cells can be programmed to build medicines from scratch, starting with a clever new approach to autoimmune disease.
